viewAmryt Pharma PLC

Amryt Pharma completes Chiasma acquisition

"The combined business will have three approved commercial products and an exciting pipeline of development assets"

Amryt Pharma PLC -

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT, FRA:3N9) has completed its acquisition of US group Chiasma Inc (NASDAQ:CHMA) with Raj Kannan and Roni Mamluk joining the board as non-executive directors.

Joe Wiley, Amryt’s chief executive, said:  “This transaction further solidifies our position as a global leader in treating rare and orphan conditions.

"The combined business will have three approved commercial products and an exciting pipeline of development assets.

"Our lead development candidate, Oleogel-S10, is currently progressing through the regulatory process in the US and EU and, if approved, will bring our portfolio of commercial products to four.

"We see significant revenue growth opportunities for Mycapssa in acromegaly and are also very excited to further develop the potential for Mycapssa in patients with carcinoid symptoms stemming from neuroendocrine tumors (“NET”) where we believe the commercial opportunity is significant.

"With the addition of NET, our combined pipeline will have four product candidates in late clinical stages as well as our exciting pre-clinical gene therapy asset, AP103 in dystrophic Epidermolysis Bullosa"

Shares in Amryt were down 1% at 150.5p.

Quick facts: Amryt Pharma PLC


Price: 180 GBX

Market Cap: £569.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Amryt reports record 2Q results and raises full-year guidance as momentum...

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT, FRA:3N9) CEO Joey Wiley joined Proactive’s Stephen Gunnion to discuss the company's second-quarter results, which show a 35.9% rise in revenue year-on-year. Wiley noting that it's the sixth consecutive quarter the company has reported positive EBITDA...

on 6/8/21

2 min read